支持使用hERG边际分布进行综合的QTc风险评估,用于来自多个实验室和多个场合的三个阳性对照剂
Derek J Leishman1, Jessica Brimecombe2, William Crumb3
1Eli Lilly and Company, Indianpolis, Indiana, USA.
Journal of pharmacological and toxicological methods
|June 9, 2024
概括
这项研究为药物安全性评估建立了可靠的hERG通道强度边缘. 这些发现支持使用30倍的hERG保证金门进行综合的QTc风险评估.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药品安全 药品安全
- 心血管安全心血管安全
背景情况:
- 评估药物阻断hERG通道的功效对于安全药理学至关重要.
- 已建立的最佳实践指南可用于可靠的hERG功效评估.
- 血度和蛋白质结合数据对于边际计算至关重要.
研究的目的:
- 使用参考代理来创建hERG保证金计算的一致分母.
- 分析实验室内和实验室间的hERG边际变化.
- 为10毫秒的QTc延长提供更新的hERG边际,并推"切断"值.
主要方法:
- 使用了12个hERG IC50"最佳实践"数据集,用于3种参考剂.
- 包括来自单个实验室 (5组) 和多个实验室 (7组) 的数据集.
主要成果:
- 分母风险分布与ICH E14/S7B指南保持一致.
- 在hERG IC50值中,病例间和实验室间的变异性是可比的.
- 药物间的差异显著影响了聚合利率的变化,建立了一个强大的参考.
结论:
- 该研究提供了对长期存在的30倍hERG利率"切断"的敏感性的见解.
- 研究人员可以使用这些分析和hERG边际值来支持负面的QTc综合风险评估.
相关概念视频
Hazard Ratio
111
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
111
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125


